P3 Health Partners

Aging Demographics And Medicare Advantage Will Redefine Primary Care

AnalystHighTarget

Not Invested

Community Contributor

Published

31 Aug 25

AnalystHighTarget's Fair Value

US$20.00

51.2% undervalued

11 Sep

US$9.76

-50.2%

18.4%

-50.2%

18.4%

You can edit this narrative until Aug 31 9:35 PM. Then, changes will post as Updates.

Author's Valuation

US$20

51.2% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$20

51.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

5.02%

Healthcare Services revenue growth rate

0.24%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

9.55%

Calculation

US$41.26m

Earnings '28

2.12x

PE Ratio '28

US$87.52m

Market Cap '28

US$87.52m

Market Cap '28

3.30m

No. shares '28

US$26.51

Share Price '28

US$26.51 Share Price '28

Discounted to 2025 @ 9.85% p.a.

US$20.00

Fair Value '25